Through Navican, patients at Intermountain can get tested on an internally developed NGS platform that gauges a range of actionable genes implicated in cancer.
Under the partnership, Myriad will be ION's preferred partner for providing hereditary testing to its member practices.
The test is designed to replace gel electrophoresis assays currently used for measuring M-proteins, biomarkers for plasma cell diseases such as multiple myeloma.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The database is intended to provide the research community with a resource of control cases to aid in the evaluation of variants of unknown significance in breast cancer.
In Science this week: convergent evolution in bird hemoglobin, and more.
The Wall Street Journal speaks with patients affected by questionable test results from Theranos.
Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.
Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.